Sage Therapeutics (SAGE) and Biogen (BIIB) announced that the U.S. FDA notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the New Drug Application for zuranolone in the treatment of major depressive disorder and postpartum depression.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SAGE: